Typhoid fever vaccination strategies

Vaccine

Volumn 33, Issue S3, 2015, Pages C55-C61

  Date, Kashmira A ^a   Bentsi Enchill, Adwoa ^b   Marks, Florian ^c   Fox, Kimberley ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c International Vaccine Institute   (South Korea)

Author keywords

Outbreak vaccination; Routine vaccination; School based vaccination; Typhoid fever; Typhoid vaccine; Vaccination strategies

Indexed keywords

TYPHOID VACCINE; BACTERIAL POLYSACCHARIDE; TY21A TYPHOID VACCINE; TYPHOID PARATYPHOID VACCINE;

COST EFFECTIVENESS ANALYSIS; ENDEMIC DISEASE; HUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SINGLE DRUG DOSE; TYPHOID FEVER; VACCINATION; ASIA; CHILD; COST BENEFIT ANALYSIS; DISEASE OUTBREAKS; ECONOMICS; EPIDEMIOLOGY; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; SOUTH AMERICA;

ASIA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; POLYSACCHARIDES, BACTERIAL; SOUTH AMERICA; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION;

EID: 84930824436     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.028     Document Type: Review

References (45)

1. Mogasale V., Maskery B., Ochiai R.L., Lee J.S., Mogasale V.V., Ramani E., et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health 2014, 2(10):e570-e580.
2. Wain J., Hendriksen R.S., Mikoleit M.L., Keddy K.H., Ochiai R.L. Typhoid fever. Lancet 2014.
3. Levine M.M., Tapia M.D., Zaidi A.K.M. Typhoid and paratyphoid (enteric) fever. Tropical infectious diseases: principles, pathogens and practice. 2011, 121-127. Saunders Elsevier. 3rd ed. R.L. Guerrant, D.H. Walker, P.F. Weller (Eds.).
4. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J. Typhoid fever. N Engl J Med 2002, 347(22):1770-1782.
5. Maskey A.P., Day J.N., Tuan P.Q., Thwaites G.E., Campbell J.I., Zimmerman M., et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006, 42(9):1247-1253.
6. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82(5):346-353.
7. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010, 50(2):241-246.
8. Chau T.T., Campbell J.I., Galindo C.M., Van Minh Hoang N., Diep T.S., Nga T.T., et al. Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007, 51(12):4315-4323.
9. Heymann D.L. Control of communicable diseases manual 2014, American Public Health Association (APHA), Washington, DC. 20th ed.
10. World Health Organization (WHO) Typhoid vaccines 2008, WHO position paper, Geneva.
11. Date K.A., Bentsi-Enchill A.D., Fox K.K., Abeysinghe N., Mintz E.D., Khan M.I., et al. Typhoid fever surveillance and vaccine use - South-East Asia and Western Pacific regions, 2009-2013. Morb Mortal Wkly Rep 2014, 63(39):855-860.
12. Slayton R.B., Date K.A., Mintz E.D. Vaccination for typhoid fever in sub-Saharan Africa. Hum Vaccine Immunother 2013, 9(4):903-906.
13. Sur D., Ochiai R.L., Bhattacharya S.K., Ganguly N.K., Ali M., Manna B., et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009, 361(4):335-344.
14. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella Typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996, 14(5):435-438.
15. World Health Organization (WHO) Immunological basis of immunization series: module 20: Salmonella enterica serovar Typhi (typhoid) vaccines. Geneva 2011.
16. Szu S.C. Development of Vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines 2013, 12(11):1273-1286.
17. World Health Organization (WHO) Expert consultation to review evidence in support of the use of typhoid conjugate vaccines 2014, July, Centre de Conférences de Varembé (CCV), Geneva, Switzerland, Geneva.
18. Thiem V.D., Lin F.Y., Canh do G., Son N.H., Anh D.D., Mao N.D., et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18(5):730-735.
19. Bhutta Z.A., Capeding M.R., Bavdekar A., Marchetti E., Ariff S., Soofi S.B., et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis 2014, 14(2):119-129.
20. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(17):1263-1269.
21. Mai N.L., Phan V.B., Vo A.H., Tran C.T., Lin F.Y., Bryla D.A., et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003, 349(14):1390-1391.
22. Government of Western Australia - Department of Health. Food handlers. Available at: [accessed 16.02.15]. http://ww2.health.wa.gov.au/Corporate/Articles/F_I/Food-handlers.
23. Khan M.I., Ochiai R.L., Clemens J.D. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines 2010, 9(5):485-496.
24. DeRoeck D., Ochiai R.L., Yang J., Anh D.D., Alag V., Clemens J.D. Typhoid vaccination: the Asian experience. Expert Rev Vaccines 2008, 7(5):547-560.
25. Dewan D.K. Community-based typhoid vaccination program in New Delhi, India. The 8th International Conference on Typhoid Fever and Other Invasive Salmonelloses 2013, Available at: http://www.coalitionagainsttyphoid.org/wp-content/uploads/2014/09/12.DewanByOchiai.8TC.pdf.
26. Yang J., Acosta C.J., Si G.A., Zeng J., Li C.Y., Liang D.B., et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial. BMC Public Health 2005, 5(May):49.
27. Khan M.I., Ochiai R.L., Hamza H.B., Sahito S.M., Habib M.A., Soofi S.B., et al. Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials 2006, 7:17.
28. Cook J., Jeuland M., Whittington D., Poulos C., Clemens J., Sur D., et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008, 26(50):6305-6316.
29. Scobie H.M., Nilles E., Kama M., Kool J.L., Mintz E., Wannemuehler K.A., et al. Impact of a targeted typhoid vaccination campaign following cyclone Tomas, Republic of Fiji, 2010. Am J Trop Med Hyg 2014, 90(6):1031-1038.
30. Namgyal P. Typhoid vaccine use in countries - progress and challenges 2010, November, Meeting of the Strategic Advisory Group of Experts, SAGE, Available at: http://www.who.int/immunization/sage/nov2010_report_typhoid_vaccines_namgyal.pdf.
31. Ferreccio C., Levine M.M., Rodriguez H., Contreras R., Committee C.T. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989, 159(4):766-769.
32. Khan M.I., Pach A., Mustafa G., Bajracharya D., Sahastrabuddhe, Bhutta W., et al. Typhoid vaccine introduction: an evidence-based pilot implementation project in Nepal and Pakistan. Vaccine 2015, 33:C62-C67.
33. Thiem V.D., Danovaro-Holliday M.C., Canh do G., Son N.D., Hoa N.T., Thuy D.T., et al. The feasibility of a school-based Vi polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a typhoid fever preventive strategy. Southeast Asian J Trop Med Public Health 2006, 37(3):515-522.
34. Agtini M.D., Ochiai R.L., Soeharno R., Lee H.J., Sundoro J., Hadinegoro S.R., et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health 2006, 120(11):1081-1087.
35. Jenkins K. Post Cyclone Tomas support to typhoid fever control in Fiji: report to AusAID. Fiji Health Sector Improvement Program 2011.
36. Tarr P.E., Kuppens L., Jones T.C., Ivanoff B., Aparin P.G., Heymann D.L. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg 1999, 61(1):163-170.
37. Yang H.H., Kilgore P.E., Yang L.H., Park J.K., Pan Y.F., Kim Y., et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001, 183(12):1775-1780.
38. Paul P., Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine 2014, 32(3):320-326.
39. Pach A., Tabbusam G., Khan M.I., Suhag Z., Hussain I., Hussain E., et al. Formative research and development of an evidence-based communication strategy: the introduction of Vi typhoid fever vaccine among school-aged children in Karachi, Pakistan. J Health Commun 2013, 18(3):306-324.
40. World Health Organization (WHO) Considerations regarding consent in vaccinating children and adolescents between 6 and 17 years old 2014, Geneva.
41. Pakkanen S.H., Kantele J.M., Kantele A. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine 2012, 30(42):6047-6053.
42. Levine M.M., Ferreccio C., Black R.E., Lagos R., Martin O.S., Blackwelder W.C. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 2007, 45(1):S8-S24.
43. Pitzer V.E., Bowles C.C., Baker S., Kang G., Balaji V., Farrar J.J., et al. Predicting the impact of vaccination on the transmission dynamics of typhoid in South Asia: a mathematical modeling study. PLoS Negl Trop Dis 2014, 8(1):e2642.
44. Carias C., Walters M., Wefula E., Date K., Swerdlow D., Vijayaraghavan M., et al. Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: the case of Kasese district in Uganda. Vaccine 2015, (in press).
45. Levin A., Wang S.A., Levin C., Tsu V., Hutubessy R. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLOS ONE 2014, 9(6):e101114.